振東製藥(300158.SZ):抗腫瘤藥物拉洛他賽脂質體系列產品創新研製和產業化項目建設完成
格隆匯11月18日丨振東製藥(300158.SZ)公佈,公司為調整公司產品結構,促進公司的可持續發展,提高公司經濟效益,於2016年6月22日召開了第三屆董事會第十八次會議,審議通過了《關於實施抗腫瘤藥物拉洛他賽脂質體系列產品創新研製和產業化項目的議案》。
目前,拉洛他賽脂質體系列產品製劑車間及配套原料藥車間已建設完成,各項指標已達到生產條件。拉洛他賽脂質微球注射液在該車間已完成多批次生產,各項技術指標達到設計要求,也符合質量標準要求。
該項目的建設完成,為一類新藥拉洛他賽的臨牀開展奠定了堅實基礎,為脂質體系列產品的開發創造了有利條件。脂質體系列產品的開發和研製進一步豐富了公司產品線,增強了核心競爭力,有利提高公司的經濟效益,促進公司的可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.